



PRESS RELEASE

PR. No. 219/2024

INTRAVENOUS INFUSIONS PLC –
UNAUDITED FINANCIAL STATEMENTS FOR
THE SIX MONTHS ENDED JUNE 30, 2024

INTRAVENOUS has released its Unaudited Financial Statements for the period ended June 30, 2024, as per the attached.

Issued in Accra, this 24th
Day of July 2024.

- E N D -

att'd.


Distribution:

1. All LDMs
2. General Public
3. Company Secretary,
4. NTHC Registrars,
5. Custodians
6. Central Securities Depository
7. Securities and Exchange Commission
8. GSE Council Members
9. GSE Notice Board

For enquiries, contact:

Head Listing, GSE on 0302 669908, 669914, 669935

*JD



INTRAVENOUS INFUSIONS PLC
MANUFACTURERS OF PHARMACEUTICAL PRODUCTS
"Saving lives since 1969"

Intravenous Infusions PLC
Unaudited Financial Statements for the
Six Months Ended 30 June 2024



INTRAVENOUS INFUSIONS PLC
MANUFACTURERS OF PHARMACEUTICAL PRODUCTS
• Serving lives since 1969

KEY FINANCIAL HIGHLIGHTS

	30 JUNE 2024 UNAUDITED GHC	30 JUNE 2023 UNAUDITED GHC	% CHANGE YOY
Revenue	12,614,849	13,570,159	-7%
Gross Profit	6,920,755	8,051,640	-14%
Finance Costs	361,318	126,343	186%
Operating Profit	980,658	2,706,911	-64%
Net Profit/(Loss) before tax	619,340	2,580,568	-76%
Net Shareholders' funds	17,825,327	16,875,435	6%
Cash and cash Equivalent	539,533	1,715,203	-69%

UNAUDITED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME

	30 JUNE 2024 UNAUDITED GHC	30 JUNE 2023 UNAUDITED GHC	% CHANGE YOY
Revenue	12,614,849	13,570,159	-7%
Cost of operations	(5,694,094)	(5,518,519)	3%
Gross profit	6,920,755	8,051,640	-14%
Other income	3,094	324	855%
Operating and other expenses	(5,943,191)	(5,345,053)	11%
Profit before finance cost and tax	980,658	2,706,911	-64%
Finance cost	(361,318)	(126,343)	186%
Profit before tax	619,340	2,580,568	-76%
Income tax expense	(116,126)	(483,857)	-76%
Profit for the period	503,214	2,096,711	-76%
Earnings per share	0.0018	0.0076	-76%



UNAUDITED STATEMENT OF FINANCIAL POSITION

	30 JUNE 2024 UNAUDITED GH¢	30 JUNE 2023 UNAUDITED GH¢	% CHANGE YOY
ASSETS			
Non-current assets			
Property, plant and equipment	23,335,267	22,230,562	5%
Investment	9,720		100%
Current assets			
Inventory	6,980,362	7,669,720	-9%
Trade and other receivables	16,823,785	20,319,882	-17%
Cash	539,533	1,715,203	-69%
Total current assets	24,343,680	29,704,805	-18%
Total assets	47,688,667	51,935,367	-8%
Equity			
Stated capital	11,626,451	11,626,451	0%
Retained earnings	4,095,756	3,145,864	30%
Capital surplus	2,103,120	2,103,120	0%
Total equity	17,825,327	16,875,435	6%
Non-Current Liability			
Deferred Tax liability	393,673	262,317	56%
Lease Obligation	34,279		100%
Medium term loan	9,973,735	13,807,378	-28%
Total Non- current liability	10,401,687	14,059,695	-26%
Current liabilities			
Borrowings	1,089,341	2,140,376	-49%
Trade and other payables	18,372,312	18,859,861	-3%
Current tax	0	0	0%
Employee Benefit obligation	0	0	0%
Total Current Liabilities	19,461,653	21,000,237	-7%
Total Liabilities	29,863,340	35,059,932	-15%
Total Liabilities and Equity	47,688,667	51,935,367	-8%



UNAUDITED STATEMENT OF CHANGES IN EQUITY

	Stated capital	Deposit for shares	Income surplus	Capital surplus	Total
Balance at 1 st Jan 2024	11,626,451		3,592,542	2,103,120	17,322,113
issue of shares(net)					
Profit/(Loss) for the period					
Dividend paid					
Transfer from profit and loss			503,314		503,314
At 30 th June 2024	11,626,451		4,095,756	2,103,120	17,825,327

UNAUDITED STATEMENT OF CASH FLOWS

	30 JUNE 2024 UNAUDITED GHC	30 JUNE 2023 UNAUDITED GHC
Operating activities		
Profit before tax	619,340	2,580,568
Adjustments for non-cash income and expenses:		
Net employee obligation		
Depreciation of property, plant and equipment	397,255	275,926
Cash flow included in operating activities	1,016,595	2,856,494
Changes in operating assets and liabilities		
Decrease/increase in trade and other receivables	(223,467)	(3,698,055)
Increase/decrease in trade payables	2,178,680	3,184,172
Increase/decrease in inventory	(720,474)	(1,042,870)
Cash flow from operating activities	2,251,334	1,299,741
Tax paid		
Dividend paid		
Net cash from operating activities	2,251,334	1,299,741
Cash flows from investing activities		
Purchases of equipment	(5,689)	(15,050)
Net cash used in investing activities	(5,689)	(15,050)



INTRAVENOUS INFUSIONS PLC
MANUFACTURERS OF PHARMACEUTICAL PRODUCTS
"Saving lives since 1989"

Cash flows from financing activities		
Increase in borrowings	(1,999,745)	(521,977)
Net cash used in financing activities	(1,999,745)	(521,977)
Net (increase/decrease) in cash and cash equivalents	(245,900)	762,714
Cash and cash equivalents at beginning of year	293,633	952,489
Cash and cash equivalents at 30 June 2024	539,533	1,715,203

Moukhtar Soalih
(Managing Director)

Eugenia Bulley
(General Manager, Finance and Administration)